With Novo's semaglutide going off patent, Indian drugmakers set to launch their cheaper generics

20th March 2026 Uncategorised 0

With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions in the country, with one company saying it will slash starter doses to 1,290 rupees ($13.79) per month.

More: With Novo's semaglutide going off patent, Indian drugmakers set to launch their cheaper generics
Source: fierce